UT M.D. Anderson Cancer Center

描述(申请人提供)：大约1000万美国人是生活在他们社区的癌症幸存者，80%的成人癌症护理是在社区肿瘤学环境中提供的。为了实施临床试验，以适当的步伐在癌症医学方面取得进展，并满足人口老龄化的重要需求，临床研究基础设施必须延伸到社区肿瘤学环境中。我们的假设是，在癌症控制护理方面的丰富临床试验，特别是在症状预防、症状管理、综合医学、癌症预防、癌症控制和癌症治疗领域的丰富临床试验，可以通过我们的研究基地通过他们所在社区的最先进药物传递给患者；随后，重要的癌症护理相关信息和方法可以从社区传回给M.D.安德森癌症中心，以增强我们的研究计划和对癌症护理的理解。我们的计划是完成现有的癌症治疗试验，不再开发进一步的治疗试验。我们将针对我们社区肿瘤学家和癌症医学领域的当前需求、癌症幸存者数量的增加以及为这一人群开发研究驱动的护理模式方面的相关挑战，以及M.D.安德森研究人员不断发展的优势，开发一个扩大的、重点关注的癌症控制研究计划。这项提议的具体目标是：目标1.在癌症控制领域进行介入临床试验，以增进受癌症影响的患者的健康；次级目标1a：在姑息治疗和康复领域开发和进行介入临床试验；次级目标1b：在支持肿瘤学领域开发和进行介入临床试验；次级目标1c：开发和进行综合医学领域的干预试验(有时称为补充和替代医学)；次级目标1d：开发和进行旨在改善癌症幸存者健康的介入试验；次级目标1e：借鉴症状评估和测量方面的最佳做法，并通过开展包括患者报告的结果衡量的干预性临床试验来扩大这些领域的知识库；次级目标1f：将新的贝叶斯方法纳入临床试验的设计和分析，其中包括使用患者报告的结果。目的2.交流医学信息、科学技术和。通过合作开发实用、创新的癌症控制试验，在我们的学术癌症中心教职员工和研究员、其他学术中心和社区肿瘤学网站之间建立最佳实践标准。我们的研究基地致力于指导我们的研究计划进行临床试验，以满足我们CCOP成员的兴趣、技能和实践环境，同时履行M.D.Anderson和NCI消除可归因于癌症及其治疗的痛苦的使命。

DESCRIPTION (provided by applicant): Approximately 10 million Americans are cancer survivors living in their communities, and 80% of adult cancer care is delivered in the community oncology setting. To implement clinical trials, make progress at an appropriate pace in cancer medicine, and address the vital needs of an aging population, the clinical research infrastructure must extend into the community oncology setting. Our hypothesis is that enriched clinical trials in cancer control care, especially in the areas of symptom prevention, symptom management, integrative medicine, cancer prevention, cancer control, and cancer treatment can be delivered to patients via state-of-the art medicine in their communities through our Research" Base; and subsequently, important cancer care-related information and approaches can be transferred back from the community to M. D. Anderson Cancer Center to enhance our research programs and our understanding of cancer care. Our plan is to complete our existing cancer treatment trials, and to develop no further treatment trials. We will develop an expanded, focused program of cancer control research in response to the current needs of our community oncologists and the field of cancer medicine, the increased number of cancer survivors and the associated challenges in developing research-driven models of care for this population, and the evolving strengths of the M. D. Anderson research faculty. The specific aims of this proposal are: Aim 1.To conduct interventional clinical trials in the realm of cancer control to enhance the health of patients affected by cancer; Sub-aim 1a: To develop and conduct interventional clinical trials in the realm of palliative care and rehabilitation; Sub-aim 1b: To develop and conduct interventional clinical trials in the realm of supportive oncology; Sub-aim 1c: To develop and conduct interventional trials that utilize interventions in the realm of integrative medicine (sometimes called complementary and alternative medicine); Sub-aim 1d: To develop and conduct interventional trials directed at improving the health of cancer survivors; Sub-aim 1e: To draw upon best practices in symptom assessment and measurement, and to expand the knowledge base in these realms through the conduct of interventional clinical trials that include patient-reported outcome measures; Sub-aim 1f: To incorporate novel Bayesian approaches to the design and analysis of clinical trials that include use of patient- reported outcomes. Aim 2. To exchange medical information, scientific technology, and. best practice standards among our academic cancer center faculty and fellows, other academic centers, and community oncology sites through collaborative development of practical, innovative cancer control trials. Our Research Base is committed to directing our research program toward conducting clinical trials to meet our CCOP members' interests, skills, and practice settings while fulfilling the mission of M. D. Anderson and the NCI to eliminate suffering attributable to cancer and its treatments.